Angion Biomedica Corp

Quick facts

Phase 3 pipeline

• ANG-3777 · Cardiovascular
  ANG-3777 is a hepatocyte growth factor (HGF) mimetic that activates the MET receptor to promote tissue repair and regeneration.

Phase 2 pipeline

• ANG-3070 · Cardiovascular
  ANG-3070 is a tyrosine kinase inhibitor that targets angiopoietin signaling to promote vascular stabilization and tissue repair.

Phase 1 pipeline

• ANG3070
• carbon-14-[14C]-ANG-3777

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Angion Biomedica Corp portfolio CI brief
• Angion Biomedica Corp pipeline updates RSS